American International Group, Inc. Terns Pharmaceuticals, Inc. Transaction History

American International Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$4.86 - $8.19 $335 - $565	69 Added 0.32%	21,370 $140,000
Q4 2023 Feb 13, 2024	SELL	$3.37 - $6.86 $289 - $589	-86 Reduced 0.4%	21,301 $138,000
Q3 2023 Nov 13, 2023	BUY	$4.7 - $8.55 $3,572 - $6,498	760 Added 3.68%	21,387 $107,000
Q2 2023 Aug 04, 2023	BUY	$7.35 - $13.29 $151,608 - $274,132	20,627 New	20,627 $180,000
Q2 2022 Aug 12, 2022	SELL	$1.5 - $3.0 $10,216 - $20,433	-6,811 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$2.83 - $6.7 $1,352 - $3,202	-478 Reduced 6.56%	6,811 $20,000
Q4 2021 Feb 11, 2022	SELL	$5.65 - $10.73 $1,231 - $2,339	-218 Reduced 2.9%	7,289 $52,000
Q3 2021 Nov 12, 2021	BUY	$7.22 - $13.46 $18,945 - $35,319	2,624 Added 53.74%	7,507 $78,000
Q2 2021 Aug 13, 2021	SELL	$12.26 - $22.0 $2,353 - $4,224	-192 Reduced 3.78%	4,883 $60,000
Q1 2021 May 07, 2021	BUY	$17.13 - $27.25 $86,934 - $138,293	5,075 New	5,075 $112,000

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $220M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.